Bausch & Lomb U.K Limited

Bausch & Lomb House, 106 London Road, Kingston-upon-Thames, Surrey, KT2 6TN, UK
Telephone: +44 (0)208 781 2900
Fax: +44 (0)208 781 2901
Medical Information Direct Line: +44(0)1748 828849 or 08 1871 9318
Medical Information e-mail: medicalinformationuk@bausch.com
Customer Care direct line: +44 (0)208781 2991


Summary of Product Characteristics last updated on the eMC: 20/09/2007
SPC Artelac SDU preservative free hypromellose 0.32%


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Artelac 0.32% w/v Eye Drops Single Dose Unit


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Hypromellose, 0.32% w/v.

For excipients, see 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Eye drops, solution.

Sterile clear solution.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Acts as a lubricant and artificial tear in the symptomatic treatment of dehydration of the cornea and conjunctiva due to impaired lacrimal secretion and functional disorders as a result of topical or systemic diseases, or caused by deficient or incomplete eyelid closure.


Go to top of the page
4.2 Posology and method of administration

4.2.1 Dosage

Suitable for use in adults and children.

Unless otherwise directed, instill 1 drop into the conjunctival sac (corner of the eye, nearest the nose) 3 to 5 times per day or as required, to provide sufficient lubrication.

Therapy of dry eye syndrome requires an individual dosage regimen.

Leave an interval of at least 5 minutes before instilling another ophthalmic medication.

4.2.2 Administration

For ocular use only.


Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substance (hypromellose) or to any of the excipients.


Go to top of the page
4.4 Special warnings and precautions for use

Stop treatment and consult a physician if irritation persists or worsens or new eye signs or symptoms develop.

Wearers of soft contact lenses should remove their lenses before Artelac is administered and should wait for at least 15 minutes before they insert them again.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None.


Go to top of the page
4.6 Pregnancy and lactation

Artelac can be used during pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

Artelac on instillation may cause a short term blurring of vision when first used. If affected wait until vision has cleared before driving or operating machinery.


Go to top of the page
4.8 Undesirable effects

Brief blurred vision or a slight stinging sensation on instilling Artelac.


Go to top of the page
4.9 Overdose

No case of overdose has been reported.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group:

Ophthalmologicals: other ophthalmologicals

ATC code: S01X A20

Hypromellose prolongs adhesion, enhances moistening of the cornea and conjunctiva and allows for a smoother movement of the conjunctiva over the cornea.


Go to top of the page
5.2 Pharmacokinetic properties

Hypromellose does not permeate the cornea or reach the systemic circulation via the ophthalmic vessels.


Go to top of the page
5.3 Preclinical safety data

There is no preclinical data of relevance to the prescriber.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Disodium phosphate dodecahydrate

Sodium dihydrogen phosphate dihydrate

Sorbitol

Purified water


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

2 years.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.


Go to top of the page
6.5 Nature and contents of container

0.5 ml single dose unit, composed of LDPE.

30, 60 or 120 single dose units.


Go to top of the page
6.6 Special precautions for disposal and other handling

Avoid contamination during use. Artelac SDU eye drops are sterile until first opened. For single use only. Each carton contains a patient insert with instructions for use.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Pharma Global Limited

Hudson Road

Sandycove

Co. Dublin

Republic of Ireland


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 11185/0002


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

25th January 2007


Go to top of the page
10. DATE OF REVISION OF THE TEXT


More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/20112/SPC/


Active Ingredients/Generics

 
   hypromellose